Previous 10 | Next 10 |
Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...
Wall Street put in a mixed performance on Wednesday. Earnings from IBM helped the Dow post a gain of nearly 250 points. However, the Nasdaq sank more than 1% after Netflix reported disappointing quarterly results. The Netflix miss had reverberations throughout the market. In response, investo...
Gainers: Clarus Therapeutics Holdings (CRXT) +87%. Winc (WBEV) +27%. AlloVir (ALVR) +26%. NexImmune (NEXI) +24%. Charah Solutions (CHRA) +22%. Target Hospitality (TH) +20%. Phio Pharmaceuticals (PHIO) +20%. Healthcare Services Group (HCSG) +19%. CEL-SCI (CVM) +18%. Biophytis (BPTS) +17%. Lose...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AlloVir (NASDAQ: ALVR ) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel. Source: JHVEPhoto / Shutterstock.com Posoleucel is AlloVir’s ...
Gainers: AlloVir (ALVR) +41%. Biophytis (BPTS) +22%. Clarus Therapeutics (CRXT) +22%. Healthcare Services (HCSG) +20%. BioSig Technologies (BSGM) +6%. Losers: Arcturus Therapeutics (ARCT) -22%. Diffusion Pharmaceuticals (DFFN) -13%. Seer (SEER) -7%. HTG Molecular...
Clarus Therapeutics (CRXT) +18%. AlloVir (ALVR) +18% on FDA regenerative medicine tag for posoleucel to prevent 6 viruses in cell transplant patients. Westwater Resources (WWR) +15% and Alabama Graphite Products break ground on Kellyton processing plant. IceCure Medical (...
The U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to AlloVir's (NASDAQ:ALVR) T cell therapy posoleucel to prevent infections and disease from six viruses that commonly impact high-risk adult and pediatric patients following...
Posoleucel’s third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies Global Phase 3 multi-virus prevention trial initiated in March 2022 and is enrolling patients AlloVir (Nasdaq: ALVR), a late clinical-stage allogene...
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life scie...
Updated, preliminary Phase 2 data presented at EBMT Annual Meeting continue to demonstrate substantial reduction in the expected rate of clinically significant infections with posoleucel therapy 21 of 24 patients were free of clinically significant infections through the Week ...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...